State of Wyoming Sells 4,576 Shares of Kymera Therapeutics, Inc. $KYMR

State of Wyoming lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 38.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,204 shares of the company’s stock after selling 4,576 shares during the period. State of Wyoming’s holdings in Kymera Therapeutics were worth $805,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of KYMR. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Kymera Therapeutics by 20.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock worth $1,747,000 after purchasing an additional 2,721 shares during the last quarter. Sterling Capital Management LLC increased its holdings in shares of Kymera Therapeutics by 378.6% in the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock valued at $215,000 after purchasing an additional 1,518 shares during the last quarter. Inspire Investing LLC acquired a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $482,000. Nisa Investment Advisors LLC increased its holdings in shares of Kymera Therapeutics by 45.9% in the third quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company’s stock valued at $232,000 after purchasing an additional 652 shares during the last quarter. Finally, Abel Hall LLC lifted its position in Kymera Therapeutics by 4.0% during the third quarter. Abel Hall LLC now owns 4,870 shares of the company’s stock worth $544,000 after buying an additional 189 shares in the last quarter.

Insider Buying and Selling

In related news, insider Brian Adams sold 6,371 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the completion of the transaction, the insider owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at $75,855,438.40. This trade represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. 15.98% of the stock is currently owned by insiders.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

Analysts Set New Price Targets

A number of equities analysts have weighed in on KYMR shares. Wall Street Zen lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. TD Cowen raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Royal Bank Of Canada lifted their price target on Kymera Therapeutics from $112.00 to $116.00 and gave the stock a “sector perform” rating in a report on Friday. Morgan Stanley boosted their price target on shares of Kymera Therapeutics from $135.00 to $146.00 and gave the company an “overweight” rating in a research report on Tuesday, October 27th. Finally, Wells Fargo & Company upped their price objective on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $137.92.

Kymera Therapeutics Stock Up 3.3%

Shares of Kymera Therapeutics stock opened at $126.63 on Friday. Kymera Therapeutics, Inc. has a 52 week low of $55.66 and a 52 week high of $130.05. The business’s fifty day simple moving average is $114.93 and its 200-day simple moving average is $96.35. The firm has a market cap of $10.53 billion, a PE ratio of -34.98 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 22.65% and a negative net margin of 285.33%. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. During the same period in the previous year, the business posted ($0.94) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -3.90 earnings per share for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.